BioSpace News Archive

Partnership Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Dedicated Staff With Clinical Expertise in Women’s Health Products

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020 Filed a New Form S-3 Shelf Registration Statement Which Replaces the Company’s Existing Shelf Registration Statement, which Expires on June 1, 2020 NORCROSS, Ga., May 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update f

– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program – – Collaboration with Merck to discover and develop certain proprietary influenza A/B antiviral agents remains ongoing – – Supply chain delay in fully owned influenza A virus program – – Norovirus program on track to complete proof-of-concept animal st

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in the second quarter SOUTH SAN FRANCISCO, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2020 and provided a corporate update. “Despite disruptions in clinical and preclinical research operati

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Research and development expenses were $18.3 million in the first quarter of 2020 as compared to $15.1 million in the same period in 2019, an increase of $3.2 mil

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. As previously reported, Ritter Pharmaceuticals is holding a special meeting of stockholders this week on May 14, 2020, at whi

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. The virtual presentation will take place on May 16, 2020 at 6:00pm ET. The abstract is currently available on the ASCRS

6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series Fireside Chat at 2:30 p.m. ET on May 15 TH RBC Capital Markets 2020 Global Healthcare Conference presentation at 1:20 p.m. ET on May 20 TH PITTSBURGH, May 11, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced to

Neurophth Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing innovative therapies for ocular and other genetic disease, today announced that the results of two clinical studies utilizing NFS-01 (rAAV2-ND4) in the treatment of Leber’s Hereditary Optic Neuropathy (LHON) will be presented in M